Vyndaqel

News

Alnylam joins three-way contest in ATTR cardiomyopathy

Alnylam has claimed FDA approval for Amvuttra in ATTR cardiomyopathy, allowing it to compete with rival therapies from Pfizer and BridgeBio.

News

EU clears AZ, Ionis' Wainzua for ATTR polyneuropathy

AstraZeneca and Ionis add an EU green light to earlier approvals in the US and UK for ATTR polyneuropathy drug Wainzua, a potential blockbuster.

News

BridgeBio gets EU nod for ATTR cardiomyopathy drug

BridgeBio and Bayer are poised to challenge Pfizer's Vyndaqel in the EU after acoramidis gets a green light for ATTR cardiomyopathy.

News

Pfizer reaches deal with NICE on Vyndaqel for ATTR-CM

Three years after turning it down for being too expensive, NICE has backed the use of Pfizer’s Vyndaqel as a treatment for transthyretin amyloidosis with cardiomyopathy (A

News

FDA approves Ionis, AZ’s Wainua for ATTR polyneuropathy

AstraZeneca and Ionis are planning a US launch next month for Wainua, their treatment for polyneuropathy in life-threatening disease transthyretin-mediated amyloidosis (AT

News

Alnylam's Onpattro clears FDA vote for ATTR-cardiomyopathy

Despite a sceptical appraisal by FDA reviewers, Alnylam's Onpattro has been recommended for approval as a treatment for transthyretin amyloidosis cardiomyopathy (ATTR-CM)

Alnylam joins three-way contest in ATTR cardiomyopathy

EU clears AZ, Ionis' Wainzua for ATTR polyneuropathy

BridgeBio gets EU nod for ATTR cardiomyopathy drug

Pfizer reaches deal with NICE on Vyndaqel for ATTR-CM

FDA approves Ionis, AZ’s Wainua for ATTR polyneuropathy

Alnylam's Onpattro clears FDA vote for ATTR-cardiomyopathy

FDA approves higher Wegovy dose via 4th priority voucher

Using AI-driven synthetic personas to take your insights fur...

Vyndaqel

Editor's Picks